Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 32 for:    Hydrogen Sulfide

Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02703467
Recruitment Status : Completed
First Posted : March 9, 2016
Results First Posted : October 21, 2019
Last Update Posted : October 21, 2019
Sponsor:
Collaborator:
Royal Brompton & Harefield NHS Foundation Trust
Information provided by (Responsible Party):
Imperial College London

Brief Summary:

The purpose of this study will be to determine whether there is any role for measuring Hydrogen Sulphide (H2S) in the exhaled breath in terms of management of the patient with asthma.

The investigators will recruit patients with a range of severity of asthma and health volunteers. Levels of Hydrogen Sulphide will be measured in exhaled breath and blood. Also exhaled Nitric Oxide, Spirometry and asthma symptom scores will be measured at each study visit. Participants will attend either 2 or 4 separate visits.

The investigators will determine whether there is a relationship between exhaled Hydrogen Sulphide and asthma severity.


Condition or disease
Asthma

Detailed Description:

Objectives:

  1. Perform a cross-sectional study in non-asthmatic subjects and asthmatic subjects of varying severities of the levels of Hydrogen Sulphide in exhaled breath in relation to the severity and control of asthma
  2. Compare the levels of exhaled Hydrogen Sulphide with exhaled Nitric Oxide.

We will recruit 30 health volunteers and 90 patients with a range of severity of asthma.

Particpants will attend for either 2 or 4 visits. At these visits the following measurements will be taken:

  1. Exhaled Hydrogen Sulphide
  2. Serum Hydrogen Sulphide

2. Exhaled Nitric Oxide 3. Spirometry 4. Asthma Symptom Score (ACQ)

The investigators will use a Hydrogen Sulphide UV fluorescent machine Model T101 (0-50 ppb to 0-20 ppm) (Cal-Bay Control Inc, USA) to measure directly on line exhaled breath Hydrogen Sulphide. This method has been used previously in normal people, but we will first determine whether there is an exhaled flow-dependence on the measurement of H2S levels. The investigators will use a hand-held Nitric Oxide machine (NO Breath) to measure Nitric Oxide in exhaled breath.

Subjects must have asthma according to one or more of the following criteria documented in the last 12 months:

  1. Improvement in FEV1 (forced expiratory volume at one second) ≥ 12% and 200ml predicted after inhalation of 400 mcg salbutamol
  2. Airway hyper-responsiveness (PC20 <8mg/ml)
  3. Diurnal variation in PEF (peak expiratory flow): amplitude % mean of twice daily PEF > 8%
  4. Decrease in pre-bronchodilator FEV1 >12% and >200mls within 4 weeks after tapering treatment with one or more of the following drugs: inhaled corticosteroids, oral corticosteroids, long-acting beta-agonists, long-acting beta-agonists and short-acting beta-agonists.

PLUS A history of wheeze occurring spontaneously or on exertion


Layout table for study information
Study Type : Observational
Actual Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma
Actual Study Start Date : August 1, 2015
Actual Primary Completion Date : June 30, 2016
Actual Study Completion Date : June 30, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Group/Cohort
Healthy
Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
Asthmatics
Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.



Primary Outcome Measures :
  1. Hydrogen Sulphide in Exhaled Breath [ Time Frame: At baseline visit ]
    Level of hydrogen sulphide in exhaled breath measured as parts per billion


Secondary Outcome Measures :
  1. FEV1 [ Time Frame: At baseline visit ]
    Forced expiratory volume in one second as percent of predicted value (%)

  2. FVC (Forced Vital Capacity) [ Time Frame: At 4 visits which occur during the study duration, up to 1 year ]
    Forced vital capacity as per cent of predicted

  3. Exhaled Nitric Oxide [ Time Frame: At 4 visits which occur during the study duration, up to 1 year ]
    Levels of nitric oxide in exhaled breath in parts per billion

  4. Blood Hydrogen Sulpide Level [ Time Frame: At 4 visits which occur during the study duration, up to 1 year ]
    Hydrogen Sulpide level measurements from blood


Biospecimen Retention:   Samples Without DNA
Serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The investigators will recruit a cohort healthy subjects by advertisement within the Hospital and within the general public (by newspaper advertisement). The investigators will also recruit subjects with asthma from paients attending Asthma Clinics at the Royal Brompton and Harefiled NHS Trust.
Criteria

Inclusion Criteria:

All patients must be able to give informed consent. The definition of the severity of their asthma will be according to the GINA (Global Initiative for Asthma) guidelines dependent on the amount of therapy needed to control asthma. The investigators will also include at least 45 patients with severe asthma defined on the basis of: Uncontrolled asthma: three or more of the following features present in any week in the previous 4 weeks:

  • Daytime symptoms more than twice per week
  • Any limitation of activities
  • Nocturnal symptoms once or more per week
  • Need for reliever treatment more than twice per week
  • Pre bronchodilator FEV1 <80% predicted or personal best OR
  • Frequent severe exacerbations (≥2 per year) OR
  • Require prescription of daily or alternate day oral corticosteroids (OCS) to achieve asthma control despite the prescription of high dose inhaled corticosteroids (>1000mcg fluticasone propionate daily or equivalent) or maintenance oral corticosteroids plus a long acting beta agonist or one other controller medication (for example anti-cholinergics, leukotriene receptor antagonists or theophylline).

Diagnosis of asthma for the asthma cohort: Subjects must have asthma according to one or more of the following criteria documented in the last 12 months

  • improvement in FEV1 ≥ 12% and 200ml predicted after inhalation of 400 mcg salbutamol
  • airway hyper-responsiveness (PC20 <8mg/ml)
  • diurnal variation in PEF: amplitude % mean of twice daily PEF > 8%
  • decrease in pre bronchodilator FEV1 >12% and >200mls within 4 weeks after tapering treatment with one or more of the following drugs: inhaled corticosteroids, oral corticosteroids, long-acting beta-agonists, long-acting beta-agonists and short-acting beta-agonists.

PLUS a history of wheeze occurring spontaneously or on exertion

Exclusion Criteria:

  • Current smoker, or Ex-smoker with a >10 year pack history or having smoked within the past 6 months.
  • Significant alternative diagnoses that may mimic or complicate asthma, in particular dysfunctional breathing, panic attacks, and overt psychosocial problems (if these are thought to be the major problem rather than in addition to severe asthma)
  • Significant other primary pulmonary disorders in particular pulmonary embolism, pulmonary hypertension, interstitial lung disease and lung cancer
  • Subjects with emphysema and bronchiectasis should only be excluded if this is thought to be the major pulmonary disorder rather than in addition to severe asthma
  • Diagnosis or current investigation of occupational asthma
  • Any subjects currently participating, or having participated within 3 months of the first dose in a study using a new molecular entity, or the first dose in any other study investigating drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02703467


Locations
Layout table for location information
United Kingdom
Royal Brompton Hospital
London, United Kingdom, SW3 6HP
Sponsors and Collaborators
Imperial College London
Royal Brompton & Harefield NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Kian F Chung, MBBS MD FRCP Imperial College London

Layout table for additonal information
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT02703467     History of Changes
Other Study ID Numbers: 13/LO/1453
First Posted: March 9, 2016    Key Record Dates
Results First Posted: October 21, 2019
Last Update Posted: October 21, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Imperial College London:
Exhaled hydrogen sulphide
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrogen Sulfide
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Gasotransmitters
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs